K药“药王”宝座将到期?Nature子刊预测司美格鲁肽合计销售额明年或超越它

每日经济新闻
24 Dec 2024

据报道,《Nature》旗下杂志近日刊发了一份2025年药物销售预测。该报告预测,从单药角度看,默沙东旗下帕博利珠单抗(Keytruda,以下简称K药)销售额将于2025年达到309.9亿美元,有望卫冕“药王”宝座。  诺和诺德的“降糖版”司美格鲁肽和礼来的降糖版替尔泊肽(均属于GLP-1制剂)紧随其后。如果将司美格鲁的“降糖版”和“减重版”合计计算,两款剂型药物销售额合计将达到356.1亿美元,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10